News and Insights
NAI Published in Pharmaceutical Compliance Monitor on the Role of the Board in Compliance
January 9, 2013
The size and number of recent settlements for regulatory compliance failures raise a key question for board members: how should the board’s fiduciary responsibility translate into concrete action? NAI Consultant Stephen Rothenberg, J.D., addresses this topic in his article, The Board’s Role in Pharmaceutical Compliance. Stephen also offers a structured approach to evaluating progress toward best-in-class compliance based on board actions and outcomes, called the Compliance Program Maturity Level.
See the full article, published in Pharmaceutical Compliance Monitor, January 2013, here.